Análise sistemática da influência do antifator de necrose tumoral [anti-TNF] sobre as taxas de infecção em pacientes com artrite reumatoide

Goh, Leslie; Jewell, Teresa; Laversuch, Catherine; Samanta, Ash

doi:10.1016/j.rbr.2012.12.001

Cited by 16 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 10–30% of patients do not respond to initial treatment with anti-TNF-α, and another 23–46% lose responsiveness over time [ 57 ]. Moreover, due to the immunosuppressive effect of blocking TNF-α, RA patients are at an increased risk of recurrent infections [ 58 ]. Anti-IL6R has been shown to be efficacious in suppressing RA [ 59 , 60 ], and it can be useful in patients not responding to other forms of treatment [ 61 ].…”

Section: Currently Used Drugs For Arthritis Therapy and Their Limimentioning

confidence: 99%

Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome

Dudics

Langan

Meka

et al. 2018

IJMS

120

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic, debilitating illness characterized by painful swelling of the joints, inflammation of the synovial lining of the joints, and damage to cartilage and bone. Several anti-inflammatory and disease-modifying drugs are available for RA therapy. However, the prolonged use of these drugs is associated with severe side effects. Furthermore, these drugs are effective only in a proportion of RA patients. Hence, there is a need to search for new therapeutic agents that are effective yet safe. Interestingly, a variety of herbs and other natural products offer a vast resource for such anti-arthritic agents. We discuss here the basic features of RA pathogenesis; the commonly used animal models of RA; the mainstream drugs used for RA; the use of well-characterized natural products possessing anti-arthritic activity; the application of nanoparticles for efficient delivery of such products; and the interplay between dietary products and the host microbiome for maintenance of health and disease induction. We believe that with several advances in the past decade in the characterization and functional studies of natural products, the stage is set for widespread clinical testing and/or use of these products for the treatment of RA and other diseases.

show abstract

Section: Currently Used Drugs For Arthritis Therapy and Their Limimentioning

confidence: 99%

Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome

Dudics

Langan

Meka

et al. 2018

IJMS

120

View full text Add to dashboard Cite

show abstract

“…Although the overall safety records of TNF-α-antagonists are outstanding, there is evidence of an increased propensity to infections, 7 – 10 in particular viral infections. Among these, varicella zoster virus (VZV), herpes simplex virus, hepatitis virus infections, and viral infections affecting the ear–nose–throat region are the most common.…”

Section: Introductionmentioning

confidence: 99%

Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

Hayderi¹,

Colson²,

Dezfoulian³

et al. 2016

PTT

View full text Add to dashboard Cite

As TNF-α is a major factor in the immune defense against herpes zoster (HZ); an increased incidence and severity of HZ cases were suspected in patients undergoing treatment with TNF antagonists. Several studies and clinical experience provided evidence that the incidence of HZ increases by twofold to threefold in this patient category. The number of severe cases of HZ, with multisegmental, disseminated cutaneous, and/or systemic involvement, is also increased. Concerning psoriasis patients under biologicals, the clinician should be more alert for an eventual HZ event, in particular during the first year of biological treatment, and be aware of the possibility of more severe HZ cases. HZ may also undergo an age-shift toward younger patients. Rapid identification of risk factors for severe HZ, such as severe prodromal pains and/or the presence of satellite lesions, is recommended. The treatment recommendations of HZ in this patient group are identical to the recently published guidelines for the management of HZ. The live attenuated viral vaccine OKA/Merck strain anti-HZ vaccination is recommended before initiating biological treatment in psoriasis patients. The new adjuvanted anti-HZ vaccine will probably also benefit patients while on biological treatment.

show abstract

A molecular insight of inflammatory cascades in rheumatoid arthritis and anti-arthritic potential of phytoconstituents

et al. 2021

View full text Add to dashboard Cite

Análise sistemática da influência do antifator de necrose tumoral [anti-TNF] sobre as taxas de infecção em pacientes com artrite reumatoide

Abstract: Current evidence suggests that anti-TNF treatment in RA is closely linked to infection. Patients need to be aware of the risk of infection together with the established benefits of TNF blockers in order to give informed consent for treatment.

Cited by 16 publications

References 52 publications

Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome

Natural Products for the Treatment of Autoimmune Arthritis: Their Mechanisms of Action, Targeted Delivery, and Interplay with the Host Microbiome

Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

A molecular insight of inflammatory cascades in rheumatoid arthritis and anti-arthritic potential of phytoconstituents

Contact Info

Product

Resources

About